+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 342 Pages
  • April 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5589920
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer - Drugs In Development, 2022, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights


The Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 5, 40, 31, 3, 2, 19, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 6, 9 and 1 molecules, respectively.

Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

IntroductionReport CoverageNasopharyngeal Cancer - Overview
Nasopharyngeal Cancer - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Nasopharyngeal Cancer - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Nasopharyngeal Cancer - Companies Involved in Therapeutics DevelopmentNasopharyngeal Cancer - Drug ProfilesNasopharyngeal Cancer - Dormant ProjectsNasopharyngeal Cancer - Discontinued ProductsNasopharyngeal Cancer - Product Development Milestones
Featured News & Press Releases
  • Apr 19, 2022: BeiGene presents updated results from phase 3 RATIONALE-309 Trial of PD-1 inhibitor Tislelizumab in first-line RM-NPC in Virtual ASCO Plenary Series
  • Apr 08, 2022: Junshi Biosciences and Coherus present results of phase 3 study of toripalimab in first line treatment of recurrent or metastatic nasopharyngeal carcinoma at 2022 AACR Annual Meeting
Mar 07, 2022: Voluntary announcement - JS001sc injection received the clinical trial approval
  • Dec 10, 2021: BeiGene presents results from phase 3 trial of Tislelizumab in nasopharyngeal cancer at ESMO Immuno-Oncology Congress 2021
  • Dec 03, 2021: Junshi Biosciences announces two additional indications for toripalimab included in China’s National Reimbursement Drug List
  • Dec 02, 2021: BeiGene to present new clinical data on Tislelizumab at ESMO IO Congress 2021
  • Nov 29, 2021: Junshi Biosciences announces approval of supplemental new drug application by NMPA for Toripalimab in combination with Cisplatin and Gemcitabine as first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma
  • Nov 20, 2021: Sichuan Kelun Pharmaceutical Co : Announcement on the acceptance of the listing application for PD-L1 new drug Tetlizumab injection by NMPA
  • Nov 01, 2021: Coherus and Junshi Biosciences announce FDA acceptance of BLA filing for toripalimab for treatment of nasopharyngeal carcinoma
  • Oct 31, 2021: Shanghai Junshi Bioscience Co: Voluntary announcement -the FDA accepted biologics license application of Toripalimab for treatment of nasopharyngeal carcinoma
  • Oct 06, 2021: Viracta Therapeutics initiates phase 1b/2 trial in Epstein-Barr Virus-Positive (EBV+) solid tumors
  • Sep 20, 2021: Pembrolizumab does not prolong overall survival compared to chemotherapy in platinum-pretreated recurrent or metastatic nasopharyngeal carcinoma
  • Sep 15, 2021: Coherus and Junshi Biosciences announce results from phase 3 study of toripalimab published in September Issue of Nature Medicine
  • Sep 01, 2021: Coherus and Junshi Biosciences announce completion of rolling BLA submission to U.S. FDA for toripalimab for the treatment of nasopharyngeal carcinoma
  • Aug 22, 2021: BeiGene announces acceptance of a supplemental biologics license application in China for tislelizumab in nasopharyngeal cancer
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
List of Tables
  • Number of Products under Development for Nasopharyngeal Cancer, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Nasopharyngeal Cancer - Pipeline by ADC Therapeutics SA, 2022
  • Nasopharyngeal Cancer - Pipeline by Advenchen Laboratories LLC, 2022
  • Nasopharyngeal Cancer - Pipeline by Akeso Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Alphamab Oncology, 2022
  • Nasopharyngeal Cancer - Pipeline by Ambrx Biopharma Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Amgen Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Apollomics Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Ascentage Pharma Group International, 2022
  • Nasopharyngeal Cancer - Pipeline by Astex Pharmaceuticals Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by AstraZeneca Plc, 2022
  • Nasopharyngeal Cancer - Pipeline by Atara Biotherapeutics Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by AVEO Pharmaceuticals Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by BeiGene Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Biomics Biotechnologies Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by BioSyngen Pte Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by BP InnoMed Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Bristol-Myers Squibb Co, 2022
  • Nasopharyngeal Cancer - Pipeline by Chengdu Wonho Biology Engineering Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by China Immunotech Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Compugen Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Eli Lilly and Co, 2022
  • Nasopharyngeal Cancer - Pipeline by EpimAb Biotherapeutics Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Eutilex Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Exelixis Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Geneius Biotechnology Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by GenFleet Therapeutics (Shanghai) Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by GeoVax Labs Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, 2022
  • Nasopharyngeal Cancer - Pipeline by Guangzhou Bairui Biomedical Technology Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Guangzhou Doublle Bioproduct Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by HRYZ (ShenZhen) Biotech Co, 2022
  • Nasopharyngeal Cancer - Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Immix BioPharma Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Immunomic Therapeutics Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Incyte Corp, 2022
  • Nasopharyngeal Cancer - Pipeline by Inhibrx Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Inmune Bio Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Innovent Biologics Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Johnson & Johnson, 2022
  • Nasopharyngeal Cancer - Pipeline by Joint Biosciences Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Karyopharm Therapeutics Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Kuur Therapeutics Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Lion TCR Pte Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Merck & Co Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Merck KGaA, 2022
  • Nasopharyngeal Cancer - Pipeline by Molecular Targeting Technologies Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Neonc Technologies Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Novartis AG, 2022
  • Nasopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Oxford Vacmedix UK Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Polaris Pharmaceuticals Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Qilu Puget Sound Biotherapeutics Corp, 2022
  • Nasopharyngeal Cancer - Pipeline by Rapa Therapeutics LLC, 2022
  • Nasopharyngeal Cancer - Pipeline by RAPT Therapeutics Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Rubius Therapeutics Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Seven and Eight Biopharmaceuticals Corp, 2022
  • Nasopharyngeal Cancer - Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Shanghai GeneChem Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Shanghai Miracogen Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Shenghe (China) Biopharmaceutical Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Soricimed Biopharma Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by TCR Cure Biopharma Technology Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Tessa Therapeutics Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by TOT Biopharm Co Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Transcenta Holding Ltd, 2022
  • Nasopharyngeal Cancer - Pipeline by Vectorite Biomedical Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Viracta Therapeutics Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Xencor Inc, 2022
  • Nasopharyngeal Cancer - Pipeline by Xiangxue Life Sciences, 2022
  • Nasopharyngeal Cancer - Pipeline by Y-Biologics Inc, 2022
  • Nasopharyngeal Cancer - Dormant Projects, 2022
  • Nasopharyngeal Cancer - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for Nasopharyngeal Cancer, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Top 10 Routes of Administration, 2022
  • Number of Products by Stage and Top 10 Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ADC Therapeutics SA
  • Advenchen Laboratories LLC
  • Akeso Inc
  • Alphamab Oncology
  • Ambrx Biopharma Inc
  • Amgen Inc
  • Apollomics Inc
  • Ascentage Pharma Group International
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • AVEO Pharmaceuticals Inc
  • BeiGene Ltd
  • Biomics Biotechnologies Co Ltd
  • BioSyngen Pte Ltd
  • BP InnoMed Ltd
  • Bristol-Myers Squibb Co
  • Chengdu Wonho Biology Engineering Co Ltd
  • Chia Tai Tianqing Pharmaceutical Group Co Ltd
  • China Immunotech Co Ltd
  • Compugen Ltd
  • Eli Lilly and Co
  • EpimAb Biotherapeutics Inc
  • Eutilex Co Ltd
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Geneius Biotechnology Inc
  • GenFleet Therapeutics (Shanghai) Inc
  • Genrix (Shanghai) Biopharmaceutical Co Ltd
  • GeoVax Labs Inc
  • GlaxoSmithKline Plc
  • Guangzhou Bairui Biomedical Technology Co Ltd
  • Guangzhou Doublle Bioproduct Inc
  • Harbin Gloria Pharmaceuticals Co Ltd
  • HRYZ (ShenZhen) Biotech Co
  • Huabo Biopharm (Shanghai) Co Ltd
  • Immix BioPharma Inc
  • ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
  • Immunomic Therapeutics Inc
  • Incyte Corp
  • Inhibrx Inc
  • Inmune Bio Inc
  • Innovent Biologics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Joint Biosciences Ltd
  • Karyopharm Therapeutics Inc
  • Kuur Therapeutics Ltd
  • Lion TCR Pte Ltd
  • Merck & Co Inc
  • Merck KGaA
  • Molecular Targeting Technologies Inc
  • Neonc Technologies Inc
  • Novartis AG
  • Ono Pharmaceutical Co Ltd
  • Oxford Vacmedix UK Ltd
  • Polaris Pharmaceuticals Inc
  • Qilu Puget Sound Biotherapeutics Corp
  • Rapa Therapeutics LLC
  • RAPT Therapeutics Inc
  • Rubius Therapeutics Inc
  • Seven and Eight Biopharmaceuticals Corp
  • Shanghai De Novo Pharmatech Co Ltd
  • Shanghai GeneChem Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Shanghai Miracogen Inc
  • Shenghe (China) Biopharmaceutical Co Ltd
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Soricimed Biopharma Inc
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • TCR Cure Biopharma Technology Co Ltd
  • Tessa Therapeutics Ltd
  • TOT Biopharm Co Ltd
  • Transcenta Holding Ltd
  • Vectorite Biomedical Inc
  • Viracta Therapeutics Inc
  • Xencor Inc
  • Xiangxue Life Sciences
  • Y-Biologics Inc